NbN3

NbN3

开发者: European College of Neuropsychopharmacology (ECNP)

中国
APP ID 复制
927272449
分类
价格
免费
内购
0个评分
医疗(免费)
昨日下载量
最近更新
2023-12-31
最早发布
2014-10-16
版本统计
  • 576天15小时

    最新版本上线距今

  • 0

    近1年版本更新次数

  • 2014-10-16

    全球最早版本上线日期

版本记录
显示信息
日期
  • 全部
每页显示条数
  • 请选择
  • 版本: 3.9.4

    版本更新日期

    2023-12-31

    NbN3

    NbN3

    更新日志

    - Bug fixes.

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
  • 版本: 3.9.3

    版本更新日期

    2023-09-27

    NbN3

    NbN3

    更新日志

    - Bug fixes.

    应用描述

    暂无应用描述数据

  • 版本: 3.9.2

    版本更新日期

    2023-09-13

    NbN3

    NbN3

    更新日志

    - Bug fixes.

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
  • 版本: 3.9.1

    版本更新日期

    2023-07-06

    NbN3

    NbN3

    更新日志

    - Bug fixes.

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
  • 版本: 3.9

    版本更新日期

    2023-05-23

    NbN3

    NbN3

    更新日志

    - Bug fixes.

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
  • 版本: 3.8

    版本更新日期

    2023-05-09

    NbN3

    NbN3

    更新日志

    - Bug fixes.

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
  • 版本: 3.7

    版本更新日期

    2023-05-05

    NbN3

    NbN3

    更新日志

    - Bug fixes.

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
  • 版本: 3.6

    版本更新日期

    2023-02-25

    NbN3

    NbN3

    更新日志

    - Bug fixes.

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
  • 版本: 3.5

    版本更新日期

    2023-02-24

    NbN3

    NbN3

    更新日志

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
    We also added 5 dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Pregnancy – Potential risk of taking the particular medication during pregnancy
    Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.

    As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
  • 版本: 3.4

    版本更新日期

    2022-01-11

    NbN3

    NbN3

    更新日志

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
    We also added 5 dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Pregnancy – Potential risk of taking the particular medication during pregnancy
    Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
    As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake

    视频/截图

    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图
    NbN3 App 截图

    应用描述

    It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
    This practice is confusing.
    • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
    • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
    • In this second edition 22 new medications were added so NbN includes now 130 medications.
    This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
    The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
     
    Therefore this nomenclature is based on:
    1. The need to treat now.
    2. Updated neuroscience insights.
    3. The judgment of the members of the taskforce.
    Along these lines, we have come up with the following proposal:
    The Nomenclature:
    Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
    We also added 4 additional dimensions
    4 Additional Dimensions:
    Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
    Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included 
    Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
    Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
    For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
     
    As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.